Awareness of, willingness to use, and experiences with Pre-exposure prophylaxis among youth in Nigeria.
Humans
Male
Nigeria
Pre-Exposure Prophylaxis
/ statistics & numerical data
HIV Infections
/ prevention & control
Female
Cross-Sectional Studies
Adolescent
Young Adult
Health Knowledge, Attitudes, Practice
Patient Acceptance of Health Care
/ statistics & numerical data
Pilot Projects
Anti-HIV Agents
/ therapeutic use
Antiretroviral therapy
HIV
Pre-exposure prophylaxis
Youth
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
25
02
2023
accepted:
19
08
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Youth (ages 14-24) in Nigeria have disproportionately high rates of new HIV infection. Pre-exposure prophylaxis could substantially reduce new infections among youth but has not been scaled up. This cross-sectional study aimed to assess Pre-exposure prophylaxis awareness, willingness to use, and prior use of Pre-exposure prophylaxis among youth in Nigeria. This is a secondary analysis of cross-sectional data from a quasi-experimental pilot study (clinical trial NCT04070287). The analysis focused on Pre-exposure prophylaxis awareness, willingness to use, and prior use among 324 youth recruited between September 2019 to March 2020. Descriptive statistics were calculated as frequencies and percentages for categorical variables and means and standard deviations for continuous variables. Of the 324 participants, the mean age and standard deviation were 21.17 (± 2.20) years. The majority were 20-24 years old (75.9%) and male (57.7%). Only 30.7% used condoms consistently over three months. Regarding Pre-exposure prophylaxis awareness and willingness, 62.6% had never heard of Pre-exposure prophylaxis, and 158 (50.1%) reported willingness to use Pre-exposure prophylaxis. Only 10 (3.2%) reported having used Pre-exposure prophylaxis. Nigerian youth have low awareness of and prior use of Pre-exposure prophylaxis. Given the gap between prior use and willingness to use Pre-exposure prophylaxis, our findings suggest missed opportunities to prevent new HIV infections among youth in Nigeria. Efforts to increase awareness and uptake of Pre-exposure prophylaxis among this population should consider youth-led Pre-exposure prophylaxis outreach efforts and effectively communicate the benefits of Pre-exposure prophylaxis to this population. NCT04070287, the Date of registration of the trial is 20-07-2019.
Sections du résumé
BACKGROUND
BACKGROUND
Youth (ages 14-24) in Nigeria have disproportionately high rates of new HIV infection. Pre-exposure prophylaxis could substantially reduce new infections among youth but has not been scaled up. This cross-sectional study aimed to assess Pre-exposure prophylaxis awareness, willingness to use, and prior use of Pre-exposure prophylaxis among youth in Nigeria.
METHODS
METHODS
This is a secondary analysis of cross-sectional data from a quasi-experimental pilot study (clinical trial NCT04070287). The analysis focused on Pre-exposure prophylaxis awareness, willingness to use, and prior use among 324 youth recruited between September 2019 to March 2020. Descriptive statistics were calculated as frequencies and percentages for categorical variables and means and standard deviations for continuous variables.
RESULTS
RESULTS
Of the 324 participants, the mean age and standard deviation were 21.17 (± 2.20) years. The majority were 20-24 years old (75.9%) and male (57.7%). Only 30.7% used condoms consistently over three months. Regarding Pre-exposure prophylaxis awareness and willingness, 62.6% had never heard of Pre-exposure prophylaxis, and 158 (50.1%) reported willingness to use Pre-exposure prophylaxis. Only 10 (3.2%) reported having used Pre-exposure prophylaxis.
CONCLUSION
CONCLUSIONS
Nigerian youth have low awareness of and prior use of Pre-exposure prophylaxis. Given the gap between prior use and willingness to use Pre-exposure prophylaxis, our findings suggest missed opportunities to prevent new HIV infections among youth in Nigeria. Efforts to increase awareness and uptake of Pre-exposure prophylaxis among this population should consider youth-led Pre-exposure prophylaxis outreach efforts and effectively communicate the benefits of Pre-exposure prophylaxis to this population.
TRIAL REGISTRATION
BACKGROUND
NCT04070287, the Date of registration of the trial is 20-07-2019.
Identifiants
pubmed: 39334111
doi: 10.1186/s12913-024-11459-1
pii: 10.1186/s12913-024-11459-1
doi:
Substances chimiques
Anti-HIV Agents
0
Banques de données
ClinicalTrials.gov
['NCT04070287']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1128Subventions
Organisme : Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ID : UG3HD096929
Organisme : National Institute of Allergy and Infectious Disease (NIAID)
ID : T32AI007001
Informations de copyright
© 2024. The Author(s).
Références
Ajayi AI, Ismail KO, Adeniyi OV, Akpan W. Awareness and use of pre-exposure and postexposure prophylaxes among Nigerian university students: findings from a cross-sectional survey. Medicine. 2018;97.
Unaids, W O R L D A I D S D A Y 2021. 2021.
UNAIDS. 90-90-90: treatment for all | UNAIDS. Miles To Go - Unaids Data 2018. 2018. https://www.unaids.org/en/resources/909090 . Accessed 22 Sep 2020.
Awofala AA, Ogundele OE. HIV epidemiology in Nigeria. Saudi J Biol Sci. 2018;25:697–703.
doi: 10.1016/j.sjbs.2016.03.006
pubmed: 29740232
Agyemang S. The extent of knowledge about HIV/AIDS among young people in the Ejura-Sekyedumase district of Ghana. J AIDS HIV Res. 2012;4:241–7.
doi: 10.5897/JAHR12.023
Badru T, Mwaisaka J, Khamofu H, Agbakwuru C, Adedokun O, Pandey SR et al. HIV comprehensive knowledge and prevalence among young adolescents in Nigeria: evidence from Akwa Ibom AIDS indicator survey, 2017. BMC Public Health. 2020;20.
Makhema J, Wirth KE, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E, et al. Universal Testing, expanded treatment, and incidence of HIV infection in Botswana. N Engl J Med. 2019;381:230–42.
doi: 10.1056/NEJMoa1812281
pubmed: 31314967
pmcid: 6800102
CDC. Latinos Race/Ethnicity HIV by Group HIV/AIDS. 2020.
Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28:841–9.
doi: 10.1016/j.annepidem.2018.06.005
pubmed: 29983236
pmcid: 6286209
NIH.gov. Pre-Exposure Prophylaxis (PrEP) | NIH. 2021. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/pre-exposure-prophylaxis-prep . Accessed 19 May 2022.
Adebowale-Tambe N, PrEP. HIV prevention drug many Nigerians need, don’t know about and can’t afford | Premium Times Nigeria. 2019. https://www.premiumtimesng.com/health/health-interviews/325209-prep-hiv-prevention-drug-many-nigerians-need-dont-know-about-and-cant-afford.html?tztc=1 . Accessed 19 Feb 2023.
Culp L, Caucci L. State adolescent consent laws and implications for HIV Pre-exposure Prophylaxis. Am J Prev Med. 2013;44:S119–24.
doi: 10.1016/j.amepre.2012.09.044
pubmed: 23253751
Sullivan PS, Giler RM, Mouhanna F, Pembleton ES, Guest JL, Jones J, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28:833–40.
doi: 10.1016/j.annepidem.2018.06.009
pubmed: 30037634
pmcid: 6286244
Hamilton DT, Goodreau SM, Jenness SM, Sullivan PS, Wang LY, Dunville RL, et al. Potential impact of HIV Preexposure Prophylaxis among Black and White adolescent sexual minority males. Am J Public Health. 2018;108:S284–91.
doi: 10.2105/AJPH.2018.304471
pubmed: 30383415
pmcid: 6215365
Albritton T, Eweka I, Fleuriscar J, Fleuriscar J, Adeyemi-Jones A, Dillon B. U.S. Food and Drug Administration approves pre-exposure prophylaxis use for adolescents: next steps. Prev Med (Baltim). 2018;116:222.
doi: 10.1016/j.ypmed.2018.08.039
Hosek S, Celum C, Wilson CM, Kapogiannis B, Delany-Moretlwe S, Bekker L-G. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa. J Int AIDS Soc. 2016;19:21107.
doi: 10.7448/IAS.19.7.21107
pubmed: 27760684
pmcid: 5071778
O’malley G, Barnabee G, Mugwanya K, THE SCIENCE OF PREVENTION (JD STEKLER AND JM BAETEN, SECTION EDITORS). Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART? 2019. https://doi.org/10.1007/s11904-019-00437-6
WHO. Global PrEP Network Highlight - March. 2021. 2021. https://www.who.int/news-room/feature-stories/detail/global-data-shows-increasing-prep-use-and-widespread-adoption-of-who-prep-recommendations . Accessed 30 Sep 2022.
Idoko J, Folayan M. The use of antiretroviral therapy for the Prevention of New HIV infection in populations at high risk for HIV Sero-conversion in Nigeria. Afr J Reprod Health. 2015;18:127–34.
Emmanuel G, Folayan M, Undelikwe G, Ochonye B, Jayeoba T, Yusuf A et al. Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. BMC Public Health 2020 20:1. 2020;20:1–10.
Ogunbajo A, Iwuagwu S, Williams R, Biello K, Mimiaga MJ. Awareness, willingness to use, and history of HIV PrEP use among gay, bisexual, and other men who have sex with men in Nigeria. PLoS ONE. 2019;14:e0226384.
doi: 10.1371/journal.pone.0226384
pubmed: 31851722
pmcid: 6919589
Adeoti AO, Demir E, Adeyemi S, Yakutcan U, Kengne AP, Kayode G et al. Impact of pre-exposure and post-exposure prophylaxes prevention programme on HIV burden and services in a low-resource setting: a simulation modelling approach. Pan Afr Med J. 2021;40.
Case KK, Gomez GB, Hallett TB. The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-saharan Africa: a scoping review of modelling contributions and way forward. J Int AIDS Soc. 2019;22.
Asuquo SE, Tahlil KM, Muessig KE, Conserve DF, Igbokwe MA, Chima KP, et al. Youth engagement in HIV prevention intervention research in sub-saharan Africa: a scoping review. J Int AIDS Soc. 2021;24:e25666.
doi: 10.1002/jia2.25666
pubmed: 33569913
pmcid: 7876473
Iwelunmor J, Tucker JD, Obiezu-Umeh C, Gbaja-Biamila T, Oladele D, Nwaozuru U et al. The 4 youth by Youth (4YBY) pragmatic trial to enhance HIV self-testing uptake and sustainability: study protocol in Nigeria. Contemp Clin Trials. 2022;114.
Iwelunmor J, Ezechi O, Obiezu-Umeh C, Gbaja-Biamila T, Musa AZ, Nwaozuru U, et al. Enhancing HIV Self-Testing among Nigerian youth: feasibility and preliminary efficacy of the 4 youth by Youth Study using Crowdsourced Youth-Led strategies. AIDS Patient Care STDS. 2022;36:64–72.
doi: 10.1089/apc.2021.0202
pubmed: 35147463
pmcid: 8861905
Tucker JD, Day S, Tang W, Bayus B. Crowdsourcing in medical research: concepts and applications. PeerJ. 2019;2019:e6762.
doi: 10.7717/peerj.6762
Tucker JD, Tang W, Li H, Liu C, Fu R, Tang S, et al. Crowdsourcing designathon: a new model for multisectoral collaboration. BMJ Innov. 2018;4:46–50.
doi: 10.1136/bmjinnov-2017-000216
World Health Organization (WHO). Crowdsourcing in Health and Health Research: A Practical Guide. The Special Programme for Research and Training in Tropical Diseases(TDR). 2018;:1–36.
NIH. Home - ClinicalTrials.gov. 2022. https://www.clinicaltrials.gov/ . Accessed 20 May 2022.
Federal Ministry of Health. Guidelines for young persons’ participation in Research and Access to sexual and Reproductive Health Services in Nigeria. Abuja; 2014.
AIDSVu. Mapping PrEP: First Ever Data on PrEP Users Across the U.S. 2018. https://aidsvu.org/prep/ . Accessed 30 Sep 2022.
Ajayi AI, Awopegba OE, Adeagbo OA, Ushie BA. Low coverage of HIV testing among adolescents and young adults in Nigeria: implication for achieving the UNAIDS first 95. PLoS ONE. 2020;15:e0233368.
doi: 10.1371/journal.pone.0233368
pubmed: 32428005
pmcid: 7237011
Durosinmi-Etti O, Nwala EK, Oki F, Ikpeazu A, Godwin E, Umoh P, et al. Communication needs for improved uptake of PrEP and HIVST services among key populations in Nigeria: a mixed-method study. AIDS Res Ther. 2021;18:1–13.
doi: 10.1186/s12981-021-00411-6
Ogunbajo A, Tsai AC, Kanki PJ, Mayer KH. Acceptability of and preferences for Long-Acting Injectable HIV PrEP and other PrEP modalities among sexual minority men in Nigeria, Africa. AIDS Behav. 2022;1:1–13.
Taggart T, Liang Y, Pina P, Albritton T. Awareness of and willingness to use PrEP among Black and Latinx adolescents residing in higher prevalence areas in the United States. PLoS ONE. 2020;15:e0234821.
doi: 10.1371/journal.pone.0234821
pubmed: 32628674
pmcid: 7337337
Taggart T, Bond KT, Ritchwood TD, Smith JC. Getting youth PrEPared: adolescent consent laws and implications for the availability of PrEP among youth in countries outside of the United States. J Int AIDS Soc. 2019;22.
Eaton LA, Matthews DD, Driffin DD, Bukowski L, Wilson PA, Stall RD. A Multi-US City Assessment of Awareness and Uptake of Pre-exposure Prophylaxis (PrEP) for HIV Prevention among Black men and Transgender women who have sex with men. Prev Sci. 2017;18:505–16.
doi: 10.1007/s11121-017-0756-6
pubmed: 28101813
pmcid: 5926200
Ajayi AI, Mudefi E, Yusuf MS, Adeniyi OV, Rala N, Goon D, Ter. Low awareness and use of pre-exposure prophylaxis among adolescents and young adults in high HIV and sexual violence prevalence settings. Medicine. 2019;98.
Idoko J, Folayan MO, Dadem NY, Kolawole GO, Anenih J, Alhassan E. Why should i take drugs for your infection? Outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria. BMC Public Health. 2015;15:1–12.
doi: 10.1186/s12889-015-1690-9
Obinna chioma. With more investment in HIV prevention, PrEP can help suppress infection — EXPERTS. 2021. https://www.vanguardngr.com/2021/06/with-more-investment-in-hiv-prevention-prep-can-help-suppress-infection-experts/ . Accessed 12 Jul 2022.
Obinna chioma. With more investment in HIV prevention, PrEP can help suppress infection — EXPERTS. 2021. https://www.vanguardngr.com/2021/06/with-more-investment-in-hiv-prevention-prep-can-help-suppress-infection-experts/ . Accessed 11 Jul 2022.
Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. Volume 31. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV; 2019. pp. 545–53.
Lunkuse JF, Kamacooko O, Muturi-Kioi V, Chinyenze K, Kuteesa MO, Price MA, et al. Low awareness of oral and injectable PrEP among high-risk adolescent girls and young women in Kampala, Uganda. BMC Infect Dis 2022. 2022;22(1):22:1–9.
Chimbindi N, Mthiyane N, Zuma T, Baisley K, Pillay D, McGrath N et al. Antiretroviral therapy based HIV prevention targeting young women who sell sex: a mixed method approach to understand the implementation of PrEP in a rural area of KwaZulu-Natal, South Africa. https://doi.org/10.1080/09540121.2021.1902933 . 2021;34:232–40.
Sila J, Larsen AM, Kinuthia J, Owiti G, Abuna F, Kohler PK, et al. High awareness, yet low uptake, of Pre-exposure Prophylaxis among adolescent girls and Young women within Family Planning clinics in Kenya. AIDS Patient Care STDS. 2020;34:336–43.
doi: 10.1089/apc.2020.0037
pubmed: 32757980
pmcid: 7415219
Birdthistle I, Mulwa S, Sarrassat S, Baker V, Khanyile D, O’Donnell D, et al. Effects of a multimedia campaign on HIV self-testing and PrEP outcomes among young people in South Africa: a mixed-methods impact evaluation of ‘MTV Shuga Down South’. BMJ Glob Health. 2022;7:e007641.
doi: 10.1136/bmjgh-2021-007641
pubmed: 35365480
pmcid: 8977807
Kahle EM, Sullivan S, Stephenson R. Functional Knowledge of Pre-Exposure Prophylaxis for HIV Prevention Among Participants in a Web-Based Survey of Sexually Active Gay, Bisexual, and Other Men Who Have Sex With Men: Cross-Sectional Study. JMIR Public Health Surveill. 2018;4(1):e13 https://publichealth.jmir.org/2018/1/e13 . 2018;4:e8089.
Shamu S, Shamu P, Khupakonke S, Farirai T, Chidarikire T, Guloba G et al. Pre-exposure prophylaxis (PrEP) awareness, attitudes and uptake willingness among young people: gender differences and associated factors in two South African districts. https://doi.org/10.1080/16549716.2021.1886455 . 2021;14.
Adepoju BP. African nations lead the world in offering PrEP HIV prevention drug. Health. 2021;3320 February:1–3.
Emmanuel G, Folayan M, Undelikwe G, Ochonye B, Jayeoba T, Yusuf A, et al. Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. BMC Public Health. 2020;20:1–10.
doi: 10.1186/s12889-020-8195-x
Ssuna B, Katahoire A, Armstrong-Hough M, Kalibbala D, Kalyango JN, Kiweewa FM. Factors associated with willingness to use oral pre-exposure prophylaxis (PrEP) in a fisher-folk community in peri-urban Kampala, Uganda. BMC Public Health. 2022;22:1–8.
doi: 10.1186/s12889-022-12859-w
Iloanusi SH, Mgbere OO, Abughosh SM, Essien EJ. HIV non-occupational post exposure Prophylaxis in Nigeria: a systematic review of Research evidence and practice. Int J Maternal Child Health AIDS. 2019;8:101.
doi: 10.21106/ijma.287
Mack N, Odhiambo J, Wong CM, Agot K. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders. BMC Health Serv Res. 2014;14:1–12.
doi: 10.1186/1472-6963-14-231
Barreras JL, Linnemayr SL, MacCarthy S. We have a stronger survival mode: exploring knowledge gaps and culturally sensitive messaging of PrEP among latino men who have sex with men and Latina transgender women in Los Angeles, CA. Volume 31. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV; 2019. pp. 1221–7.
García M, Harris AL. PrEP awareness and decision-making for Latino MSM in San Antonio, Texas. PLoS ONE. 2017;12.
Yoshioka E, Giovenco D, Kuo C, Underhill K, Hoare J, Operario D. I’m doing this test so I can benefit from PrEP: exploring HIV testing barriers/facilitators and implementation of pre-exposure prophylaxis among South African adolescents. https://doi.org/10.2989/16085906.2020.1743726 . 2020;19:101–8.